Medtronic Plc

Medtronic delivered <a href="https://247wallst.com/investing/2026/02/17/medtronic-just-posted-its-best-quarter-in-2-5-years/">its strongest quarter in years</a> during fiscal Q3 2026, posting non-GAAP diluted EPS of $1.36, ahead of the $1.34 consensus estimate by 1.87%, while revenue of $9.02 billion grew 8.7% year over year and edged past the $8.89 billion Wall Street forecast by 1.40%. The standout driver was the Cardiovascular Portfolio, which generated $3.46 billion with 13.8% reported growth, fueled in large part by Cardiac Ablation Solutions revenue jumping 80% overall and 137% in the U.S. as the company's pulsed field ablation lineup gained rapid clinical adoption. The result marked the company's strongest enterprise revenue performance in 10 quarters and exceeded Medtronic's own organic growth guidance by 50 basis points. Additional momentum came from the Hugo robotic surgery system receiving U.S. FDA clearance and strong double-digit international growth in the Diabetes segment. Looking ahead, Medtronic reiterated its full-year outlook for approximately 5.5% organic revenue growth and non-GAAP EPS of $5.62 to $5.66, absorbing an estimated $185 million tariff headwind.